The Center for Drug Evaluations of the National Medical Products Administration (NMPA) in China has accepted the biologics license application (BLA) for zanidatamab for second-line treatment of HER2-positive biliary tract cancer (BTC).
This is good news for Zymeworks (Nasdaq: ZYME), a Canadian biotech that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. Shares in the company were more than 2% higher early in Tuesday morning's trading in New York.
Zanidatamab is a bispecific antibody developed using Zymeworks’ proprietary Azymetric platform that can simultaneously bind two non-overlapping epitopes of HER2, known as biparatopic binding. It is being advanced in multiple cancer types in partnership with US biopharma Jazz Pharmaceuticals (Nasdaq: JAZZ) and Sino-American biotech BeiGene (Nasdaq: BGNE).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze